Here, we first reported that MAPK pathway mutations in HNSCC predict remarkably long patient survival, even among patients bearing TP53 mutations (median ∼14 yr), much longer than that of HPV-positive HNSCC (median ∼5.5 yr). This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.